Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma ...
Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The mo ...
UTOPIA Phase 3 Trial of UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC - Abhishek Srivastava
Abhishek Srivastava presents UTOPIA trial data, covering UGN-103, a reformulation of intravesical mitomycin reverse thermal hydrogel, in recurrent low-grade intermediate-risk non-muscle-invasive ...
Aurea Molina Diaz discusses the PrInCIS-NIADY, a nationwide Spanish real-world study of adjuvant nivolumab in patients with high-risk PD-L1-positive muscle-invasive urothelial carcinoma following ...
(UroToday.com) The 2026 ASCO annual meeting featured a radioligand innovation in prostate cancer session and a presentation by Dr. Michael Morris discussing CONVERGE-01 Part 3 assessing Ac-225 ...
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. Andrea Malgeri presented a reconstructed individual ...
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. Robert Motzer presented the final analysis of the ...
(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a management and prevention of frequent side effects and modifying the metabolism session, and a ...
(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a high-risk and locally advanced prostate cancer session and a presentation by Dr. Jason Efstathiou ...
(UroToday.com) The 2026 SESAUA annual meeting featured the Gee-Dineen lecture series and a presentation by Dr. Andrew Harris discussing the state of the Urology workforce. Dr. Harris started his ...
ASCO 2025 Phase 1/2 Duravelo-1 study, nectin-4–targeting zelenectide pevedotin (BT8009), pembrolizumab, cisplatin-ineligible patients, locally advanced or metastatic urothelial cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results